Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models

Gastroenterology Research and Practice

Volumn 2015, Issue , 2015, Pages

  De Moreno De Leblanc, Alejandra ^a   Del Carmen, Silvina ^a   Chatel, Jean Marc ^b   Miyoshi, Anderson ^c   Azevedo, Vasco ^c   Langella, Philippe ^b   Bermúdez Humarán, Luis G ^b   Leblanc, Jean Guy ^a  

^a CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

^b UMR1319 MICALIS   (France)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; LACTIC ACID;

ANIMAL MODEL; BACTERIAL STRAIN; COLITIS; DNA MODIFICATION; GENE TARGETING; GENETICALLY MODIFIED LACTIC ACID BACTERIA; INFLAMMATORY BOWEL DISEASE; LACTIC ACID BACTERIUM; NONHUMAN; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84929646195     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2015/146972     Document Type: Review

References (64)

1. P. J. Basso, M. T. Fonseca, G. Bonfá et al., "Association among genetic predisposition, gut microbiota, and host immune response in the etiopathogenesis of inflammatory bowel disease,"Brazilian Journal of Medical and Biological Research, vol. 47, no. 9, pp. 727-737, 2014.
2. E. De Greef, Y. Vandenplas, B. Hauser, T. Devreker, and G. Veereman, "The use of probiotics in IBD and IBS," Minerva Pediatrica, vol. 66, no. 5, pp. 491-500, 2014.
3. S. del Carmen, J. G. LeBlanc, and A. de Moreno de LeBlanc, "Use of probiotics in the treatment of Crohn's disease," in Crohn's Disease: Etiology, Diagnosis and Treatment Options, J. G. LeBlanc and A. de Moreno de LeBlanc, Eds., pp. 287-306, Nova Science, Hauppauge, NY, USA, 2013.
4. C. Hill, F. Guarner, G. Reid et al., "Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic," Nature Reviews Gastroenterology &Hepatology, vol. 11, no. 8, pp. 506-514, 2014.
5. K. L. Madsen, J. S. Doyle, L. D. Jewell, M. M. Tavernini, and R. N. Fedorak, "Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice," Gastroenterology, vol. 116, no. 5, pp. 1107-1114, 1999.
6. L. O'Mahony, M. Feeney, S. O'Halloran et al., "Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice," Alimentary Pharmacology and Therapeutics, vol. 15, no. 8, pp. 1219-1225, 2001.
7. T. R. Klaenhammer, "Bacteriocins of lactic acid bacteria," Biochimie, vol. 70, no. 3, pp. 337-349, 1988.
8. M. C. Rea, E. Clayton, P. M. O'Connor et al., "Antimicrobial activity of lacticin 3147 against clinical Clostridium difficile strains," Journal of Medical Microbiology, vol. 56, no. 7, pp. 940-946, 2007.
9. A. de Moreno de LeBlanc, S. Chaves, and G. Perdigón, "Effect of yoghhurt on the cytokine profile using a murine model of intestinal inflammation," European Journal of Inflammation, vol. 7, no. 2, pp. 97-109, 2009.
10. S. Chaves, G. Perdigon, and A. de Moreno de LeBlanc, "Yoghurt consumption regulates the immune cells implicated in acute intestinal inflammation and prevents the recurrence of the inflammatory process in a mouse model," Journal of Food Protection, vol. 74, no. 5, pp. 801-811, 2011.
11. E. M. Fernandez, V. Valenti, C. Rockel et al., "Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide," Gut, vol. 60, no. 8, pp. 1050-1059, 2011.
12. R. K. Duary, M. A. Bhausaheb, V. K. Batish, and S. Grover, "Anti-inflammatory and immunomodulatory efficacy of indig enous probiotic Lactobacillus plantarum Lp91 in colitis mouse model,"Molecular Biology Reports, vol. 39, no. 4, pp. 4765-4775, 2012.
13. E. Zagato, E. Mileti, L. Massimiliano et al., "Lactobacillus paracasei CBA L74 metabolic products and fermented milk for infant formula have anti-inflammatory activity on dendritic cells in vitro and protective effects against colitis and an enteric pathogen in vivo," PLoS ONE, vol. 9, no. 2, Article ID e87615, 2014.
14. G. Kaci, D. Goudercourt, V. Dennin et al., "Anti-inflammatory properties of Streptococcus salivarius, a commensal bacterium of the oral cavity and digestive tract," Applied and Environmental Microbiology, vol. 80, no. 3, pp. 928-934, 2014.
15. K. Madsen, A. Cornish, P. Soper et al., "Probiotic bacteria enhance murine and human intestinal epithelial barrier function,"Gastroenterology, vol. 121, no. 3, pp. 580-591, 2001.
16. S. C. Ng, A. L. Hart, M. A. Kamm, A. J. Stagg, and S. C. Knight, "Mechanisms of action of probiotics: recent advances," Inflammatory Bowel Diseases, vol. 15, no. 2, pp. 300-310, 2009.
17. Y. Mao, S. Nobaek, B. Kasravi et al.,"The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats,"Gastroenterology, vol. 111, no. 2, pp. 334-344, 1996.
18. C. Caballero-Franco, K. Keller, C. De Simone, and K. Chadee, "The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells," The American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 292, no. 1, pp. G315-G322, 2007.
19. L. Kruidenier and H. W. Verspaget, "Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease - radicals or ridiculous?" Alimentary Pharmacology and Therapeutics, vol. 16, no. 12, pp. 1997-2015, 2002.
20. G. Grompone, P. Martorell, S. Llopis et al.,"Anti-inflammatory Lactobacillus rhamnosus CNCM I-3690 strain protects against oxidative stress and increases lifespan in Caenorhabditis elegans,"PLoS ONE, vol. 7, no. 12, Article ID e52493, 2012.
21. S. Drouault, G. Corthier, S. D. Ehrlich, and P. Renault, "Survival, physiology, and lysis of Lactococcus lactis in the digestive tract,"Applied and Environmental Microbiology, vol. 65, no. 11, pp. 4881-4886, 1999.
22. J. G. LeBlanc, C. Aubry, N. G. Cortes-Perez et al., "Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update," FEMS Microbiology Letters, vol. 344, no. 1, pp. 1-9, 2013.
23. A. Miyoshi, L. G. Bermúdez-Humarán, M. S. P. D. Azevedo, P. Langella, and V. Azevedo, "Lactic acid bacteria as live vectors: heterologous protein production and delivery systems,"in Biotechnology of Lactic Acid Bacteria Novel Applications, F. Mozzi, R. R. Raya, and G. M. Vignolo, Eds., pp. 161-176, Wiley-Blackwell, Ames, Iowa, USA, 2010.
24. B. G. Spyropoulos, E. P. Misiakos, C. Fotiadis, and C. N. Stoidis, "Antioxidant properties of probiotics and their protective effects in the pathogenesis of radiation-induced enteritis and colitis,"Digestive Diseases and Sciences, vol. 56, no. 2, pp. 285-294, 2011.
25. W. Han, A. Mercenier, A. Ait-Belgnaoui et al., "Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase," Inflammatory Bowel Diseases, vol. 12, no. 11, pp. 1044-1052, 2006.
26. I. M. Carroll, J. M. Andrus, J. M. Bruno-Bárcena, T. R. Klaenhammer, H. M. Hassan, and D. S. Threadgill, "Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis," The American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 293, no. 4, pp. G729-G738, 2007.
27. J. G. LeBlanc, S. del Carmen, A. Miyoshi et al., "Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice," Journal of Biotechnology, vol. 151, no. 3, pp. 287-293, 2011.
28. L. Watterlot, T. Rochat, H. Sokol et al., "Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice,"International Journal of Food Microbiology, vol. 144, no. 1, pp. 35-41, 2010.
29. T. Rochat, A. Miyoshi, J. J. Gratadoux et al., "High-level resistance to oxidative stress in Lactococcus lactis conferred by Bacillus subtilis catalase KatE," Microbiology, vol. 151, no. 9, pp. 3011-3018, 2005.
30. A. de Moreno de LeBlanc, S. Chaves, G. Perdigón et al., "Oral administration of a catalase-producing Lactococcus lactis can prevent a chemically induced colon cancer in mice," Journal of Medical Microbiology, vol. 57, no. 1, pp. 100-105, 2008.
31. T. Rochat, L. G. Bermúdez-Humarán, J.-J. Gratadoux et al., "Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganese-dependant catalase on DSS-induced colitis in mice," Microbial Cell Factories, vol. 6, article 22, 2007.
32. A. de Moreno de LeBlanc and G. Perdigón, "Yogurt feeding inhibits promotion and progression of experimental colorectal cancer," Medical Science Monitor, vol. 10, no. 4, pp. BR96-BR104, 2004.
33. S. del Carmen, A. de Moreno de LeBlanc, R. Martin et al., "Genetically engineered immunomodulatory Streptococcus thermophilus strains producing antioxidant enzymes exhibit enhanced anti-inflammatory activities," Applied and Environmental Microbiology, vol. 80, no. 3, pp. 869-877, 2014.
34. S. Mocellin, F. Marincola, C. R. Rossi, D. Nitti, and M. Lise, "The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle," Cytokine &Growth Factor Reviews, vol. 15, no. 1, pp. 61-76, 2004.
35. A. de Moreno de LeBlanc, S. del Carmen, M. Zurita-Turk et al., "Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases," ISRN Gastroenterology, vol. 2011, Article ID 892971, 11 pages, 2011.
36. N. Egilmez and K. Sikora, "Method for treating inflammatory bowel disease by oral administration of IL-10," Google Patents, 2005.
37. G. J. Marlow, D. van Gent, and L. R. Ferguson, "Why interleukin-10 supplementation does not work in Crohn's disease patients," World Journal of Gastroenterology, vol. 19, no. 25, pp. 3931-3941, 2013.
38. N. Huyghebaert, A. Vermeire, S. Neirynck, L. Steidler, E. Remaut, and J. P. Remon, "Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10," European Journal of Pharmaceutics and Biopharmaceutics, vol. 60, no. 3, pp. 349-359, 2005.
39. J. O. Lindsay, A. Sandison, P. Cohen, F. M. Brennan, and H. J. F. Hodgson, "IL-10 gene therapy is therapeutic for dextran sodium sulfate-induced murine colitis," Digestive Diseases and Sciences, vol. 49, no. 7-8, pp. 1327-1334, 2004.
40. H. Nakase, K. Okazaki, Y. Tabataetal., "New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease," Journal of Pharmacology and Experimental Therapeutics, vol. 301, no. 1, pp. 59-65, 2002.
41. L. Schotte, L. Steidler, J. Vandekerckhove, and E. Remaut, "Secretion of biologically active murine interleukin-10 by Lactococcus lactis," Enzyme and Microbial Technology, vol. 27, no. 10, pp. 761-765, 2000.
42. L. Steidler, W. Hans, L. Schotte et al., "Treatment of murine colitis by Lactococcus lactis secreting interleukin-10," Science, vol. 289, no. 5483, pp. 1352-1355, 2000.
43. L. Steidler, S. Neirynck, N. Huyghebaert et al., "Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10," Nature Biotechnology, vol. 21, no. 7, pp. 785-789, 2003.
44. H. Braat, P. Rottiers, D. W. Hommes et al., "A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease," Clinical Gastroenterology and Hepatology, vol. 4, no. 6, pp. 754-759, 2006.
45. B. Benbouziane, P. Ribelles, C. Aubry et al., "Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces," Journal of Biotechnology, vol. 168, no. 2, pp. 120-129, 2013.
46. V. Guimarães, S. Innocentin, J.-M. Chatel et al., "A new plasmid vector for DNA delivery using lactococci," Genetic Vaccines and Therapy, vol. 7, article 4, 2009.
47. S. Innocentin, V. Guimarães, A. Miyoshi et al., "Lactococcus lactis expressing either Staphylococcus aureus fibronectin-binding protein A or Listeria monocytogenes internalin A can efficiently internalize and deliver DNA in human epithelial cells," Applied and Environmental Microbiology, vol. 75, no. 14, pp. 4870-4878, 2009.
48. A. Miyoshi, E. Jamet, J. Commissaire, P. Renault, P. Langella, and V. Azevedo, "A xylose-inducible expression system for Lactococcus lactis," FEMS Microbiology Letters, vol. 239, no. 2, pp. 205-212, 2004.
49. S. Termont, K. Vandenbroucke, D. Iserentant et al., "Intracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance," Applied and Environmental Microbiology, vol. 72, no. 12, pp. 7694-7700, 2006.
50. T. D. Luerce, A. C. Gomes-Santos, C. S. Rocha et al., "Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis," Gut Pathogens, vol. 6, no.1, article 33, 2014.
51. S. del Carmen, A. de Moreno de Leblanc, G. Perdigón et al., "Evaluation of the anti-inflammatory effect of milk fermented by a strain of IL-10-producing lactococcus lactis using a murine model of Crohn's disease," Journal of Molecular Microbiology and Biotechnology, vol. 21, no. 3-4, pp. 138-146, 2012.
52. R. Martín, F. Chain, S. Miquel et al., "Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation,"Human Vaccines & Immunotherapeutics, vol. 10, no. 6, pp. 1611-1621, 2014.
53. S. del Carmen, M. Zurita-Turk, F. Alvarenga Lima et al., "A novel interleukin-10 DNA mucosal delivery system attenuates intestinal inflammation in a mouse model," European Journal of Inflammation, vol. 11, no. 3, pp. 641-654, 2013.
54. J. F. Almeida, D. Mariat, V. Azevedo et al., "Correlation between fibronectin binding protein A expression level at the surface of recombinant lactococcus lactis and plasmid transfer in vitro and in vivo," BMC Microbiology, vol. 14, article 248, 2014.
55. M. Zurita-Turk, S. del Carmen, A. C. Santos et al., "Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis," BMC Biotechnology, vol. 14, no. 1, p. 73, 2014.
56. S. del Carmen, R. Martín Rosique, T. Saraiva et al., "Protective effects of Lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model," Journal of Clinical Gastroenterology, vol. 48, supplement 1, pp. S12-S17, 2014.
57. K. Vandenbroucke, H. de Haard, E. Beirnaert et al., "Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis," Mucosal Immunology, vol. 3, no. 1, pp. 49-56, 2010.
58. H. Yoshida and M. Yoshiyuki, "Regulation of immune responses by interleukin-27," Immunological Reviews, vol. 226, no. 1, pp. 234-247, 2008.
59. M. L. Hanson, J. A. Hixon, W. Li et al., "Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice,"Gastroenterology, vol. 146, no. 1, pp. 210.e13-221.e13, 2014.
60. L. G. Bermúdez-Humarán, J. P. Motta, C. Aubry et al., "Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci," Microbial Cell Factories, vol. 14, no. 1, article 26, 2015.
61. S. Caluwaerts, K. Vandenbroucke, L. Steidler et al., "AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis," Oral Oncology, vol. 46, no. 7, pp. 564-570, 2010.
62. K. Vandenbroucke, W. Hans, J. Van Huysse et al., "Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice," Gastroenterology, vol. 127, no. 2, pp. 502-513, 2004.
63. J. P. Motta, L. Magne, D. Descamps et al., "Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis," Gastroenterology, vol. 140, no. 4, pp. 1272-1282, 2011.
64. T. Saraiva, K. Morais, V. Pereira et al., "Milk fermented with a 15-lipoxygenase-1-producing Lactococcus lactis alleviates symptoms of colitis in a murine model," Current Pharmaceutical Biotechnology, vol. 16, no. 5, pp. 424-429, 2015.